Thiomersal

Thiomersal (INN), or thimerosal (USAN, JAN), is an organomercury compound. This compound is a well-established antiseptic and antifungal agent.

Thiomersal
Names
IUPAC name
Ethyl(2-mercaptobenzoato-(2-)-O,S) mercurate(1-) sodium
Other names
Mercury((o-carboxyphenyl)thio)ethyl sodium salt
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.000.192
EC Number
  • 200-210-4
RTECS number
  • OV8400000
UNII
Properties
C9H9HgNaO2S
Molar mass 404.81 g/mol
Appearance White or slightly yellow powder
Density 2.508 g/cm3[1]
Melting point 232 to 233 °C (450 to 451 °F; 505 to 506 K) (decomposition)
1000 g/l (20 °C)
Pharmacology
D08AK06 (WHO)
Hazards
Safety data sheet External MSDS
GHS pictograms
GHS Signal word Danger
GHS hazard statements
 H300, H310, H330, H373, H410
P260, P273, P280, P301, P310, P330, P302, P352, P310, P304, P340, P310[2]
NFPA 704 (fire diamond)
Flammability code 1: Must be pre-heated before ignition can occur. Flash point over 93 °C (200 °F). E.g. canola oilHealth code 3: Short exposure could cause serious temporary or residual injury. E.g. chlorine gasReactivity code 1: Normally stable, but can become unstable at elevated temperatures and pressures. E.g. calciumSpecial hazards (white): no code
1
3
1
Flash point 250 °C (482 °F; 523 K)
Lethal dose or concentration (LD, LC):
75 mg/kg (oral, rat)[3]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Y verify (what is YN ?)
Infobox references

The pharmaceutical corporation Eli Lilly and Company gave thiomersal the trade name Merthiolate. It has been used as a preservative in vaccines, immunoglobulin preparations, skin test antigens, antivenins, ophthalmic and nasal products, and tattoo inks.[4] In spite of the scientific consensus that fears about its safety are unsubstantiated,[5][6][7][8] its use as a vaccine preservative was controversial, and it was phased out from routine childhood vaccines in the European Union, and a few other countries in response to popular fears.[9]

History

Morris Kharasch, a chemist then at the University of Maryland filed a patent application for thiomersal in 1927;[10] Eli Lilly later marketed the compound under the trade name Merthiolate.[11] In vitro tests conducted by Lilly investigators H. M. Powell and W. A. Jamieson found that it was forty to fifty times as effective as phenol against Staphylococcus aureus.[11] It was used to kill bacteria and prevent contamination in antiseptic ointments, creams, jellies, and sprays used by consumers and in hospitals, including nasal sprays, eye drops, contact lens solutions, immunoglobulins, and vaccines. Thiomersal was used as a preservative (bactericide) so that multidose vials of vaccines could be used instead of single-dose vials, which are more expensive. By 1938, Lilly's assistant director of research listed thiomersal as one of the five most important drugs ever developed by the company.[11]

Structure

Thiomersal features mercury(II) with a coordination number 2, i.e. two ligands are attached to Hg, the thiolate and the ethyl group. The carboxylate group confers solubility in water. Like other two-coordinate Hg(II) compounds, the coordination geometry of Hg is linear, with a 180° S-Hg-C angle. Typically, organomercury thiolate compounds are prepared from organomercury chlorides.[1]

Uses

Thiomersal's main use is as an antiseptic and antifungal agent, due to the oligodynamic effect. In multidose injectable drug delivery systems, it prevents serious adverse effects such as the Staphylococcus infection that, in one 1928 incident, killed 12 of 21 children vaccinated with a diphtheria vaccine that lacked a preservative.[12] Unlike other vaccine preservatives used at the time, thiomersal does not reduce the potency of the vaccines that it protects.[11] Bacteriostatics such as thiomersal are not needed in single-dose injectables.[13]

In the United States, countries in the European Union, and a few other affluent countries, thiomersal is no longer used as a preservative in routine childhood vaccination schedules.[9] In the U.S., the only exceptions among vaccines routinely recommended for children are some formulations of the inactivated influenza vaccine for children older than two years.[14] Several vaccines that are not routinely recommended for young children do contain thiomersal, including DT (diphtheria and tetanus), Td (tetanus and diphtheria), and TT (tetanus toxoid); other vaccines may contain a trace of thiomersal from steps in manufacture.[12] The multi-dose versions of the influenza vaccines Fluvirin and Fluzone can contain up to 25 micrograms of mercury per dose from thiomersal.[15][16] Also, four rarely used treatments for pit viper, coral snake, and black widow venom still contain thiomersal.[17] Outside North America and Europe, many vaccines contain thiomersal; the World Health Organization has concluded that there is no evidence of toxicity from thiomersal in vaccines and no reason on safety grounds to change to more expensive single-dose administration.[18] The United Nations Environment Program backed away from an earlier proposal of adding thiomersal in vaccines to the list of banned compounds in a treaty aimed at reducing exposure to mercury worldwide.[19] Citing that eliminating the preservative in multi-dose vaccines, primarily used in developing countries, would lead to high cost and a requirement for refrigeration which the developing countries can ill afford, the UN's final decision at the Minamata Convention on Mercury in 2013 was to exclude thiomersal from the treaty.[20]

Toxicology

General toxicity

Thiomersal is very toxic by inhalation, ingestion, and in contact with skin (EC hazard symbol T+), with a danger of cumulative effects. It is also very toxic to aquatic organisms and may cause long-term adverse effects in aquatic environments (EC hazard symbol N).[21] In the body, it is metabolized or degraded to ethylmercury (C2H5Hg+) and thiosalicylate.[12]

Cases have been reported of severe mercury poisoning by accidental exposure or attempted suicide, with some fatalities.[22] Animal experiments suggest that thiomersal rapidly dissociates to release ethylmercury after injection; that the disposition patterns of mercury are similar to those after exposure to equivalent doses of ethylmercury chloride; and that the central nervous system and the kidneys are targets, with lack of motor coordination being a common sign. Similar signs and symptoms have been observed in accidental human poisonings. The mechanisms of toxic action are unknown.

Fecal excretion accounts for most of the elimination from the body. Ethylmercury clears from blood with a half-life of about 18 days in adults by breakdown into other chemicals, including inorganic mercury. Ethylmercury is eliminated from the brain in about 14 days in infant monkeys. Risk assessment for effects on the nervous system have been made by extrapolating from dose-response relationships for methylmercury.[23] Methylmercury and ethylmercury distribute to all body tissues, crossing the blood–brain barrier and the placental barrier, and ethylmercury also moves freely throughout the body.[24]

Concerns based on extrapolations from methylmercury caused thiomersal to be removed from U.S. childhood vaccines, starting in 1999. Since then, it has been found that ethylmercury is eliminated from the body and the brain significantly faster than methylmercury, so the late-1990s risk assessments turned out to be overly conservative.[23] Though inorganic mercury metabolized from ethylmercury has a much longer half-life in the brain, at least 120 days, it appears to be much less toxic than the inorganic mercury produced from mercury vapor, for reasons not yet understood.[23]

As an allergen
Patch test

Thiomersal is used in patch testing for people who have dermatitis, conjunctivitis, and other potentially allergic reactions. A 2007 study in Norway found that 1.9% of adults had a positive patch test reaction to thiomersal;[25] a higher prevalence of contact allergy (up to 6.6%) was observed in German populations.[26] Thiomersal-sensitive individuals can receive intramuscular rather than subcutaneous immunization,[27] though there have been no large sample sized studies regarding this matter to date. In real-world practice on vaccination of adult populations, contact allergy does not seem to elicit clinical reaction.[26]

Thiomersal allergy has decreased in Denmark, probably because of its exclusion from vaccines there.[28] In a recent study of Polish children and adolescents with chronic/recurrent eczema, positive reactions to thiomersal were found in 11.7% of children (7–8 y.o.) and 37.6% of adolescents (16–17 y.o.). This difference in the sensitization rates can be explained by changing exposure patterns: The adolescents have received six thiomersal-preserved vaccines during their life course, with the last immunization taking place 2–3 years before the mentioned study, younger children received only four thiomersal-preserved vaccines, with the last one applied five years before the study, while further immunizations were performed with new thiomersal-free vaccines.[29]

Disproven autism hypothesis
Main article: Thiomersal and vaccines

Following a review of mercury-containing food and drugs mandated in 1999, the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics asked vaccine manufacturers to remove thiomersal from vaccines as a purely precautionary measure, and it was rapidly phased out of most U.S. and European vaccines.[11][30] Many parents saw the action to remove thiomersal—in the setting of a perceived increasing rate of autism as well as increasing number of vaccines in the childhood vaccination schedule—as indicating that the preservative was the cause of autism.[11] The scientific consensus is that there is no evidence supporting these claims, and the rate of autism continues to climb despite elimination of thiomersal from routine childhood vaccines.[7][31][32][33] Major scientific and medical bodies such as the Institute of Medicine[33] and World Health Organization,[34][35] as well as governmental agencies such as the Food and Drug Administration[12] and the CDC[36] reject any role for thiomersal in autism or other neurodevelopmental disorders.[37] This controversy has caused harm due to parents attempting to treat their autistic children with unproven and possibly dangerous treatments, discouraging parents from vaccinating their children due to fears about thiomersal toxicity,[38] and diverting resources away from research into more promising areas for the cause of autism.[39] Thousands of lawsuits have been filed in a U.S. federal court to seek damages from alleged toxicity from vaccines, including those purportedly caused by thiomersal.[40]

gollark: I AM TYPIJNG OINE HANDED OPLOEASE EXCUSE ANY MISTAKES>
gollark: BECAUSE IJTERNET.
gollark: Change your name to some has'kell.
gollark: It's not a central government applying the tax. It's a syndicate of puppy-kicking organizations backed by military power.
gollark: Example: anarcho-capitalism but with a 10% tax used to fund puppy-kicking organizations.

See also
  • Argyrol – Antiseptic containing compounded solutions of mild silver protein, a silver containing antimicrobial
  • Nitromersol, a related antimicrobial

References
  1. Melnick, J. G.; Yurkerwich, K.; Buccella, D.; Sattler, W.; Parkin, G. (2008). "Molecular Structures of Thimerosal (Merthiolate) and Other Arylthiolate Mercury Alkyl Compounds". Inorg. Chem. 47 (14): 6421–26. doi:10.1021/ic8005426. PMID 18533648.
  2. "Thimerosal T5125".
  3. Chambers, Michael. "ChemIDplus – 54-64-8 – RTKIYNMVFMVABJ-UHFFFAOYSA-L – Thimerosal [USP:JAN] – Similar structures search, synonyms, formulas, resource links, and other chemical information". chem.sis.nlm.nih.gov. Retrieved 3 April 2018.
  4. Sharpe, M. A.; Livingston, A. D.; Baskin, D. S. (2012). "Thimerosal-Derived Ethylmercury is a Mitochondrial Toxin in Human Astrocytes: Possible Role of Fenton Chemistry in the Oxidation and Breakage of mtDNA". Journal of Toxicology. 2012: 1–12. doi:10.1155/2012/373678. PMC 3395253. PMID 22811707. ...widely used in medical products, including as a preservative in vaccines, immunoglobulin preparations, skin test antigens, antivenins, ophthalmic and nasal products, and tattoo inks...
  5. Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine (2004). Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. ISBN 978-0-309-09237-1.CS1 maint: multiple names: authors list (link)
  6. Doja, Asif; Roberts, Wendy (November 2006). "Immunizations and autism: a review of the literature". Can J Neurol Sci. 33 (4): 341–46. doi:10.1017/s031716710000528x. PMID 17168158.
  7. "Vaccines Do Not Cause Autism". cdc.gov. Retrieved 29 November 2015.
  8. Gołoś, A; Lutyńska, A (2015). "Thiomersal-containing vaccines - a review of the current state of knowledge". Przeglad Epidemiologiczny. 69 (1): 59–64, 157–61. PMID 25862449.
  9. Bigham, M; Copes, R (2005). "Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease". Drug Saf. 28 (2): 89–101. doi:10.2165/00002018-200528020-00001. PMID 15691220.
  10. U.S. Patent 1,672,615 "Alkyl mercuric sulphur compound and process of producing it".
  11. Baker, JP (2008). "Mercury, Vaccines, and Autism: One Controversy, Three Histories". Am J Public Health. 98 (2): 244–53. doi:10.2105/AJPH.2007.113159. PMC 2376879. PMID 18172138.
  12. "Thimerosal in vaccines". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. June 3, 2008. Retrieved July 25, 2008.
  13. "Thimerosal in Vaccines: Frequently Asked Questions". Food and Drug Administration. Retrieved 9 March 2008.
  14. Coordinating Center for Infectious Diseases (October 26, 2007). "Thimerosal in seasonal influenza vaccine". Centers for Disease Control and Prevention. Archived from the original on April 11, 2008. Retrieved April 2, 2008.
  15. "Seasonal Influenza Vaccine Supply for the U.S. 2016-2017 Influenza Season | Seasonal Influenza (Flu) | CDC". cdc.gov. Retrieved March 16, 2017.
  16. Grohskopf, Lisa A.; Sokolow, Leslie Z.; Broder, Karen R.; Olsen, Sonja J.; Karron, Ruth A.; Jernigan, Daniel B.; Bresee, Joseph S. (2016). "Prevention and Control of Seasonal Influenza with Vaccines". MMWR. Recommendations and Reports. 65 (5): 1–54. doi:10.15585/mmwr.rr6505a1. ISSN 1057-5987. PMID 27560619.
  17. "Mercury in plasma-derived products". U.S. Food and Drug Administration. September 9, 2004. Archived from the original on September 29, 2007. Retrieved October 1, 2007.
  18. Global Advisory Committee on Vaccine Safety (July 14, 2006). "Thiomersal and vaccines". World Health Organization. Retrieved November 20, 2007.
  19. Hamilton, Jon (17 December 2012). "Doctors Argue Against Proposed Ban on Vaccine Preservative". NPR. Retrieved 25 February 2013.
  20. Sulaski Wyckoff, Alyson (January 22, 2013). "Global ban on mercury grants exception to thimerosal-containing vaccines". American Academy of Pediatrics. Retrieved August 24, 2019.
  21. "Safety data sheet, Thiomersal Ph Eur, BP, USP" (PDF). Merck. June 12, 2005. Retrieved January 1, 2010.
  22. Clarkson, TW (2002). "The three modern faces of mercury". Environ Health Perspect. 110 (S1): 11–23. doi:10.1289/ehp.02110s111. PMC 1241144. PMID 11834460. Archived from the original on September 6, 2008.
  23. Clarkson, TW; Magos, L (2006). "The toxicology of mercury and its chemical compounds". Crit Rev Toxicol. 36 (8): 609–62. doi:10.1080/10408440600845619. PMID 16973445.
  24. Clarkson, TW; Vyas, JB; Ballatori, N (2007). "Mechanisms of mercury disposition in the body". Am J Ind Med. 50 (10): 757–64. doi:10.1002/ajim.20476. PMID 17477364.
  25. Dotterud, LK; Smith-Sivertsen, T (2007). "Allergic contact sensitization in the general adult population: a population-based study from Northern Norway". Contact Dermatitis. 56 (1): 10–15. doi:10.1111/j.1600-0536.2007.00980.x. PMID 17177703.
  26. Uter, W; Ludwig, A; Balda, BR (2004). "The prevalence of contact allergy differed between population-based and clinic-based data". J Clin Epidemiol. 57 (6): 627–32. doi:10.1016/j.jclinepi.2003.04.002. PMID 15246132.
  27. Aberer, W (1991). "Vaccination despite thimerosal sensitivity". Contact Dermatitis. 24 (1): 6–10. doi:10.1111/j.1600-0536.1991.tb01621.x. PMID 2044374.
  28. Thyssen, JP; Linneberg, A; Menné, T; Johansen, JD (2007). "The epidemiology of contact allergy in the general population – prevalence and main findings". Contact Dermatitis. 57 (5): 287–99. doi:10.1111/j.1600-0536.2007.01220.x. PMID 17937743.
  29. Czarnobilska, E; Obtulowicz, K; Dyga, W; Spiewak, R (2011). "The most important contact sensitizers in Polish children and adolescents with atopy and chronic recurrent eczema as detected with the extended European Baseline Series". Pediatr Allergy Immunol. 22 (2): 252–56. doi:10.1111/j.1399-3038.2010.01075.x. PMID 20969635.
  30. "Thimerosal in vaccines: frequently asked questions (FAQs)". Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. June 7, 2007. Retrieved July 22, 2008.
  31. DeStefano, F (2007). "Vaccines and autism: evidence does not support a causal association". Clin Pharmacol Ther. 82 (6): 756–59. doi:10.1038/sj.clpt.6100407. PMID 17928818.
  32. Doja, A; Roberts, W (2006). "Immunizations and autism: a review of the literature". Can J Neurol Sci. 33 (4): 341–46. doi:10.1017/s031716710000528x. PMID 17168158.
  33. Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine (2004). Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. ISBN 978-0-309-09237-1.CS1 maint: multiple names: authors list (link)
  34. World Health Organization (2006). "Thiomersal and vaccines: questions and answers". Retrieved May 19, 2009.
  35. WHO. "Statement on thiomersal". www.who.int. Retrieved 3 April 2018.
  36. Centers for Disease Control (February 8, 2008). "Mercury and vaccines (thimerosal)". Archived from the original on April 18, 2018. Retrieved May 19, 2009.
  37. Sugarman, SD (2007). "Cases in vaccine court – legal battles over vaccines and autism". N Engl J Med. 357 (13): 1275–77. doi:10.1056/NEJMp078168. PMID 17898095.
  38. Harris, G; O'Connor, A (June 25, 2005). "On autism's cause, it's parents vs. research". New York Times. Retrieved March 11, 2016.
  39. Offit, PA (2007). "Thimerosal and vaccines – a cautionary tale". N Engl J Med. 357 (13): 1278–79. doi:10.1056/NEJMp078187. PMID 17898096.
  40. Autism cases in vaccine court:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.